PMEF
PMVP icon

Point72 Middle East FZE’s PMV Pharmaceuticals PMVP Stock Holding History

Point72 Middle East FZE’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,642
Closed -$41.2K – 1964
2023
Q1 		$41.2K Buy
8,642
+376
+5% +$2.65K ﹤0.01% 1301
2022
Q4 		$71.9K Buy
+8,266
New +$88.1K ﹤0.01% 1368

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Middle East FZE's PMVP Position: Q2 2023 in Review

Point72 Middle East FZE sold out of PMV Pharmaceuticals (PMVP) in Q2 2023, closing a stake of 8,642 shares — an estimated $41.2K sold.

Point72 Middle East FZE first reported a position in PMVP in Q4 2022 and held it in 2 quarters. The position peaked at $71.9K in Q4 2022. 106 funds tracked by Wall St. Rank hold PMVP as of Q2 2023.

  • Point72 Middle East FZE reported no remaining PMV Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 8,642 PMV Pharmaceuticals shares in Q2 2023, an estimated $41.2K.
  • Point72 Middle East FZE first reported a position in PMV Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's PMV Pharmaceuticals position peaked at $71.9K in Q4 2022.
  • 106 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.